Inhibrx Biosciences
- Market cap
- 1.37B
- P/E (TTM)i
- -10.51
- P/Bi
- -25.93
- EPSi
- -9.04
- Div yieldi
- 0.00%
- 52W posi
- 51%
Anonymous reader poll. Unscientific, not investment advice.
About Inhibrx Biosciences
Inhibrx Biosciences, Inc. is a clinical-stage biopharmaceutical company, which includes a pipeline of novel biologic therapeutic candidates, developed using proprietary modular protein engineering platforms. Its clinical pipeline of therapeutic candidates includes INBRX-109 and INBRX-106, both of which utilize multivalent formats where the precise valency can be optimized in a target-centric way to mediate what is believed to be the most appropriate agonist function. The company was founded by Brendan P. Eckelman on January 8, 2024 and is headquartered in La Jolla, CA.
- Founded
- 2024
- CEO
- Mr. Mark Paul Lappe
- Employees
- 110
- Headquarters
- La Jolla, California, United States of America
- Fiscal year end
- 12-31
- Website
- inhibrx.com
Company profile
- Exchange
- US
- Symbol
- INBX
- Market-cap rank
- #3022
- Listing date
- 2024-05-28
- Market cap
- 1.37B
- Float cap
- 801.86M
- Shares out
- 14.72M
- Float shares
- 8.59M
Sectors & themes
Quote time 2026-10-07 19:54:59 · For reference only, not investment advice and not tailored to your situation.